Tirzepatide outperforms semaglutide 20.2% vs 13.7%

Obesity drugs are now in their head-to-head era. That matters because the market has been full of indirect comparisons, marketing claims, and social-media summaries that blur what was actually tested. The new thing here is simple — Eli Lilly’s SURMOUNT-5 trial directly compared tirzepatide with semaglutide in adults with obesity, and tirzepatide won by a wide margin over 72 weeks. The final results landed in The New England Journal of Medicine on May 12, 2025. ### What actually got compared? This was a phase 3b, randomized, open-label trial in 751 adults with obesity, or overweight plus a complication, but without type 2 diabetes. Patients were assigned to the maximum tolerated dose of weekly tirzepatide — 10 mg or 15 mg — or weekly semaglutide — 1.7 mg or 2.4 mg — for 72 weeks. (nature.com) ### What were the headline results? The headline number is the one making the rounds online, and it’s real. Average weight loss was 20.2% with tirzepatide versus 13.7% with semaglutide. Lilly translates that into about 50 pounds lost versus 33 pounds. The gap is big enough that this was not a squeaker — tirzepatide delivered about 47% greater relative weight reduction in this trial. (acc.org) ### Why might tirzepatide do better? Semaglutide targets GLP-1. Tirzepatide hits GLP-1 and GIP. Basically, tirzepatide works through a broader incretin signal, which seems to push appetite suppression and energy intake lower in many patients. That does not mean everyone responds the same way, but the direct trial result suggests the mechanistic difference is showing up in real-world-scale weight loss. (investor.lilly.com) ### Does this settle the whole debate? Not quite. The trial was open-label, not blinded, and it tested maximum tolerated doses, which matters because tolerability can shape outcomes. It also focused on people without diabetes, so you should not assume the exact same gap in every population. But for the question most people were asking — which drug causes more weight loss in obesity — this is the cleanest answer yet. (acc.org) ### What about fat loss versus muscle loss? This is the part social posts often flatten. Rapid weight loss from GLP-1–based drugs does not come from fat alone. Recent reviews note that roughly 26% to 45% of weight lost in some analyses may come from lean mass, which is why clinicians keep worrying about muscle, strength, and function — not just the number on the scale. (acc.org) ### Can exercise and protein help? Yes — and this is where the practical advice is stronger than the viral numbers. A recent nutrition review argues resistance training and adequate protein should be standard companions to GLP-1 therapy because they may blunt lean-mass loss. A randomized trial also showed that adding exercise to GLP-1 treatment preserved bone density better than GLP-1 therapy alone during weight loss. (nature.com) That is not the same as proving a precise “90% fat-mass” figure from social media, but it does support the broader point that body composition matters. ### So what changed for patients? The pecking order got clearer. If the goal is maximum average weight loss, tirzepatide now has direct comparative evidence over semaglutide in obesity. But the catch is that “more weight loss” is not the whole story — access, side effects, cost, adherence, and muscle preservation still shape what the best choice looks like for any one person. (sciencedirect.com) ### Bottom line The viral 20.2% versus 13.7% claim is grounded in a real, published head-to-head trial. Tirzepatide came out ahead. But the smarter takeaway is two-part — these drugs are getting more effective, and the conversation is shifting from simple weight loss to quality of weight loss. (nature.com) (investor.lilly.com)